SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications ta…
Author: Business Wire
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today r…
AOPO Joins with National Partners to Boost Number of Minority Organ Donors
MCLEAN, Va.–(BUSINESS WIRE)– #AOPO–Association of Organ Procurement Organizations addresses need for more organ donors within minority communities with new action plan and partnership.
Global Uveitis Epidemiology Forecast Research Report 2021-2029 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Uveitis – Epidemiology Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The report includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of uveiti…
Le groupe Polpharma Biologics annonce que sa coentreprise Bioeq a soumis une demande de licence biologique (BLA) pour le biosimilaire du ranibizumab auprès de la Food and Drug Administration (FDA) américaine.
Varsovie, Pologne–(BUSINESS WIRE)–Le groupe Polpharma Biologics annonce que sa coentreprise créée avec Santo Holding (groupe Strüngmann), Bioeq, a soumis une demande de licence biologique (BLA) auprès de la Food and Drug Administration (FDA) américai…
Riassunto: Il gruppo Polpharma Biologics annuncia la presentazione, da parte della sua joint venture Bioeq, di una domanda di licenza biologica (BLA) per Ranibizumab biosimilare alla Food and Drug Administration (FDA) degli Stati Uniti
VARSAVIA, Polonia–(BUSINESS WIRE)–Il gruppo Polpharma Biologics annuncia che Bioeq, la sua joint venture con Santo Holding (Strüngmann Group), ha presentato una domanda di licenza biologica (BLA) alla Food and Drug Administration (FDA) degli Stati Un…
Die Polpharma Biologics Group meldet, dass ihr Joint-Venture-Unternehmen Bioeq für das Ranibizumab-Biosimilar einen Biologika-Lizenzantrag (BLA) bei der FDA eingereicht hat
WARSCHAU, Polen–(BUSINESS WIRE)–Die Polpharma Biologics Group meldet, dass ihr mit der Santo Holding (Strüngmann Group) gegründetes Joint-Venture-Unternehmen Bioeq für den Biosimilar-Kandidaten des Augenarzneimittels Ranibizumab (Lucentis®) einen Bio…
Resumen: Polpharma Biologics Group anuncia que su empresa en participación Bioeq ha presentado una solicitud de licencia biológica (BLA) para el biosimilar ranibizumab ante la FDA estadounidense
VARSOVIA, Polonia–(BUSINESS WIRE)–Polpharma Biologics Group anuncia que su empresa en participación con Santo Holding (Strüngmann Group), Bioeq, ha presentado una solicitud de licencia biológica (BLA, por sus siglas en inglés) ante la administración …
Samenvatting: Polpharma Biologics Group kondigt aan dat haar joint venture Bioeq een Biologics License Application (BLA) voor Biosimilar Ranibizumab heeft ingediend bij de Amerikaanse Food and Drug Administration (FDA)
WARSCHAU, Polen–(BUSINESS WIRE)–Polpharma Biologics Group kondigt aan dat haar joint venture met Santo Holding (Strüngmann Group), Bioeq, een biologische licentieaanvraag (BLA) heeft ingediend bij de Amerikaanse Food and Drug Administration (FDA) voo…
Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
WARSAW, Poland–(BUSINESS WIRE)– #biologics–Polpharma Biologics Group joint venture Bioeq has submitted a BLA for biosimilar Ranibizumab.
Glaukos Corporation Announces Second Quarter 2021 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…
Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
Visus Therapeutics to Host First Capital Markets Day in New York City on August 31, 2021
SEATTLE–(BUSINESS WIRE)–Visus Therapeutics to host its First Capital Markets Day in New York City on August 31, 2021 from 10am to 2pm ET at Convene, 530 Fifth Avenue.
Heru, the Wearable Diagnostic and Vision Augmentation Leader, Launches Commercial Availability of re:Vive in Partnership with Vision Source
HOUSTON–(BUSINESS WIRE)–Heru launches commercial availability of re:Vive, its wearable diagnostics and visual field application, with launch partner, Vision Source.
Eyevensys lève 12 millions de dollars dans un tour de table série B Plus
PARIS et CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Eyevensys, une société privée de biotechnologie au stade clinique qui développe des thérapies géniques non virales pour les maladies oculaires, annonce aujourd’hui qu’elle a levé 12 millions de dollar…
Encellin Closes $5.9M Seed Financing Co-Led by Khosla Ventures and SV Latam Capital
SAN FRANCISCO–(BUSINESS WIRE)– #biotech–Encellin Closes $5.9M Seed Financing co-led by Khosla Ventures and SV Latam Capital
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended J…
LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for …
NovaBay Pharmaceuticals to Hold Second Quarter 2021 Conference Call on August 12
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and six months ended June 30, 2021 after market close on Thursday, August 12, 2021 and will hold an invest…
Global Dry Eye Disease Drug Pipeline Research Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Disease – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Dry Eye Disease – Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipel…